# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT Sbc753e4d30
CUTOFF DATE (today): 2026-04-08
Regulator: SEBI (IN)
Matter: SEBI consultation: uniform time lag for sharing and usage of price data for educational purposes
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S365a5bde85
CUTOFF DATE (today): 2024-07-29
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S24b6400e89
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: proposed amendments to the certification regime for associated persons in the securities markets
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-11-06 | official-forward (B) | consultation_paper | "Consultation paper on Amendments to SEBI (Certification of Associated Persons in the Securities Markets) Regulations, 2007" | www.sebi.gov.in
   Claims: Proposes reviewing/expanding the definition of 'Associated Persons' under CAPSM Regulations, 2007. / Proposes changes to the manner of obtaining the NISM certificate required under the regulations. / Proposes allowing an electronic mode of participation for Continuing Professional Education (CPE) programs. / Proposes reviewing the exception criteria governing the manner of obtaining the certificate (e.g. age/experience-based exemptions).
   Excerpt: To solicit comments / views / suggestions from the public and other stakeholders on the proposed amendments to 'SEBI (Certification of Associated Persons in the Securities Markets) Regulations, 2007 ("CAPSM Regulations")'. The following proposals are being made: 1.1.1 Review / Expansion of the definition of 'Associated Persons' 1.1.2 Manner of obtaining certificate 1.1.3 Inclusion of electronic mode of participation for Continuing Professional Education (CPE) programs 1.1.4 Reviewing the exception criteria for manner of obtaining certificate.
---
## SNAPSHOT Se8ba78babd
CUTOFF DATE (today): 2022-11-06
Regulator: FDA (US)
Matter: FDA draft guidance: Drug Products Labeled as Homeopathic
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9b1b12fefe
CUTOFF DATE (today): 2023-03-03
Regulator: FDA (US)
Matter: FDA draft guidance: Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S8dac3245b9
CUTOFF DATE (today): 2023-02-19
Regulator: FDA (US)
Matter: FDA draft guidance: Mitigation Strategies To Protect Food Against Intentional Adulteration
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-02-13 | official-forward (B) | draft_guidance_availability_notice | "Mitigation Strategies To Protect Food Against Intentional Adulteration; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA, we, or Agency) is announcing the availability of a supplemental draft guidance for industry entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration: Guidance for Industry." This supplemental draft guidance document, when finalized, will
   Excerpt: The Food and Drug Administration (FDA, we, or Agency) is announcing the availability of a supplemental draft guidance for industry entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration: Guidance for Industry." This supplemental draft guidance document, when finalized, will help food facilities that manufacture, process, pack, or hold food, and that are required to register under the Federal Food, Drug, and Cosmetic Act (FD&C Act) comply with the requirements of our regulation entitled "Mitigation Strategies to Protect Food Against Intentional Adulteration."
---
## SNAPSHOT Sf178aa4a6a
CUTOFF DATE (today): 2026-02-04
Regulator: SEBI (IN)
Matter: SEBI consultation: draft circular defining the AUM threshold for 'Significant Indices' under the Index Providers Regulations
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-01-19 | official-forward (B) | draft_circular_for_comment | "Consultation Paper on Circular under SEBI (Index Providers) Regulations, 2024" | www.sebi.gov.in
   Claims: Proposes a draft circular specifying the cumulative AUM threshold (and calculation method) above which an index is a 'Significant Index' under Index Providers Regulations, 2024, triggering regulatory applicability to its Index Provider. / Proposes the threshold at cumulative domestic mutual-fund AUM exceeding Rs 20,000 crore, computed as a monthly daily-average AUM. / States the draft circular's methodology and threshold were developed based on internal deliberations and discussions with the Association of Mutual Funds in India (AMFI).
   Excerpt: SEBI has notified the regulatory framework for Index Providers in the securities market through the SEBI (Index Provider) Regulations, 2024... with the objective of fostering transparency and accountability in governance and administration of Indices. The significant indices under the regulation were defined as 'Indices administered by an Index Provider, which are tracked or benchmarked by domestic mutual fund schemes with the cumulative assets under management exceeding the limits as may be specified from time to time.' Based on the internal deliberations and discussions with Association of Mutual Funds in India (AMFI), the draft circular proposing the mentioned limit... is placed at Annexure-1.
---
## SNAPSHOT Sf3b5766514
CUTOFF DATE (today): 2026-08-17
Regulator: SEBI (IN)
Matter: SEBI consultation: framework for an IT Resilience Index for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6e9a297fc3
CUTOFF DATE (today): 2026-03-16
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing minimum investment in Social Impact Funds and NPO registration/minimum-subscription requirements on the Social Stock Exchange
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S63bb3c38aa
CUTOFF DATE (today): 2021-01-13
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-04-21 | official-forward (B) | draft_guidance_availability_notice | "Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug Application; Draft Guidance for Industry an" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that are intended to treat emergent, life- threatening conditions, it is essential to ensure that the emergency- use injector will reliably deliver the drug or biological product as intended. This is particularly critical for drugs when failure of the injector may prevent adequate delivery of a life-saving drug to a patient. The draft guidance describes the technical considerations for demonstrating reliability of emergency-use injectors under a biologics license application (BLA), new drug application (NDA), or abbreviated new drug application (ANDA).
---
## SNAPSHOT S0647f362ec
CUTOFF DATE (today): 2021-10-27
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-09-23 | official-forward (B) | draft_guidance_availability_notice | "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations." The Patient Engagement Advisory Committee (PEAC) recommended that FDA and industry develop some typ
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations." The Patient Engagement Advisory Committee (PEAC) recommended that FDA and industry develop some type of framework to clarify how patient advisors can engage in the clinical investigation process. This draft guidance focuses on the applications, perceived barriers, and common challenges of patient engagement in the design and conduct of medical device clinical investigations. This draft guidance is not final nor is it in effect at this time.
---
## SNAPSHOT S68de664d3b
CUTOFF DATE (today): 2026-05-22
Regulator: SEBI (IN)
Matter: SEBI consultation: modifying nomination norms for demat accounts and mutual fund folios
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-03-17 | official-forward (B) | consultation_paper | "Consultation Paper on Modified norms for Nomination in Demat accounts and Mutual Fund Folios" | www.sebi.gov.in
   Claims: Seeks comments on modifying the January 10, 2025 nomination-facility circular for demat accounts and mutual fund folios, aligning more closely with banking-sector nomination norms. / Proposes dropping the facility empowering a nominee to operate an account/folio while the investor is alive but incapacitated, citing high implementation cost, audit-trail difficulty, and fraud/misuse/legal-dispute risk. / Notes certain provisions of the January 2025 circular were already deferred by a December 11, 2025 circular due to operational challenges.
   Excerpt: This Consultation Paper seeks comments / suggestions from the public to modify the circular on 'Revise and revamp Nomination Facilities in the Indian Securities Market' ('Circular') dated January 10, 2025, in order to enhance the ease of investor on-boarding and ease the nomination process by aligning with the banking norms on nomination. SEBI issued the circular on January 10, 2025 for demat accounts and MF folios, w.e.f. March 01, 2025. To address certain operational challenges, the implementation of certain provisions of the circular were deferred vide circular dated December 11, 2025.
---
## SNAPSHOT Sa034caed7d
CUTOFF DATE (today): 2025-09-13
Regulator: FDA (US)
Matter: FDA draft guidance: Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S3e7129c433
CUTOFF DATE (today): 2025-11-17
Regulator: SEBI (IN)
Matter: SEBI consultation: clarifying the timeline for transferring unclaimed amounts to the investor protection fund for listed non-convertible securities
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-10-24 | official-forward (B) | consultation_paper | "Consultation paper for review of LODR Regulations - Clarification regarding the timeline for transfer of unclaimed amount by entity having listed non-convertible securities" | www.sebi.gov.in
   Claims: Proposes amending Regulation 61A(3) of LODR Regulations, 2015 to clarify the timeline for transferring unclaimed interest/dividend/redemption amounts to the Investor Education and Protection Fund (IEPF)/Investor Protection and Education Fund (IPEF). / Seeks to align the transfer timeline for entities with listed non-convertible securities with Companies Act provisions. / Frames the change as an ease-of-doing-business measure that would also benefit investors with a longer claim window.
   Excerpt: CONSULTATION PAPER, DEPARTMENT OF DEBT AND HYBRID SECURITIES, Consultation paper for review of LODR Regulations - clarification regarding the timeline for transfer of unclaimed amount by entity having listed non-convertible securities, October 2025.
---
## SNAPSHOT S9bd7653742
CUTOFF DATE (today): 2026-03-17
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing base price and price band methodology for Exchange Traded Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-13 | official-forward (B) | consultation_paper | "Consultation Paper on Review of provisions related to Base Price and Price Bands for Exchange Traded Funds (ETFs)" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to revise the base price and price-band methodology specifically for Exchange Traded Funds (equity, debt and commodity ETFs including Gold/Silver ETFs). / Notes the current fixed price band of +/-20% (+/-5% for Overnight ETFs) is applied to a base price equal to the T-2 day NAV of the ETF, creating a one-trading-day lag. / Frames the issue as the fixed band and NAV lag not being commensurate with the price range of the ETF's underlying assets.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals on Base Price and Price Bands for Exchange Traded Funds (ETFs). ETF is a mutual fund scheme that invests in securities in the same proportion as an index of securities and the units of exchange traded fund are mandatorily listed and traded on exchange platform... Currently, there are individual scrip wise price bands of up to 20% either way, applicable for all scrips in the rolling settlement except for the scrips on which derivatives products are available.
---
## SNAPSHOT S8ef6703593
CUTOFF DATE (today): 2020-12-01
Regulator: FDA (US)
Matter: FDA draft guidance: Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated With Internal or External Hemorrhoids
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S49f3ad46f7
CUTOFF DATE (today): 2025-11-15
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S5850a4fe34
CUTOFF DATE (today): 2026-06-16
Regulator: FDA (US)
Matter: FDA draft guidance: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S23fd8a9e5d
CUTOFF DATE (today): 2021-03-25
Regulator: FDA (US)
Matter: FDA draft guidance: Premenopausal Women With Breast Cancer: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-10-08 | official-forward (B) | draft_guidance_availability_notice | "Premenopausal Women With Breast Cancer: Developing Drugs for Treatment; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Premenopausal Women with Breast Cancer: Developing Drugs for Treatment." This draft guidance provides recommendations regarding the inclusion of premenopausal women in breast ca
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Premenopausal Women with Breast Cancer: Developing Drugs for Treatment." This draft guidance provides recommendations regarding the inclusion of premenopausal women in breast cancer clinical trials. The guidance is intended to assist stakeholders, including sponsors and institutional review boards, responsible for the development and oversight of clinical trials for breast cancer drugs.
---
## SNAPSHOT S7f475b9b77
CUTOFF DATE (today): 2022-12-15
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.